AstraZeneca Forms Joint Venture with Wuxi AppTec to Accelerate Biologics Development in China
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)
Published: 26 Sep-2012
DOI: 10.3833/pdr.v2012.i9.1805 ISSN: 1756-7874
Section: Joint Venture
Fulltext:
Abstract
AstraZeneca has formed a joint venture (JV) with Chinese CRO WuXi AppTec to accelerate the development and commercialisation of MEDI5117, an antibody therapeutic targeting interleukin-6 that is being developed for autoimmune and inflammatory diseases, in China...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS